Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Israel

- PMLiVE

Pfizer, BioNTech’s COVID-19 vaccine prevents 90% of infections in initial late-stage study data

Preliminary results could warrant regulatory approval soon

- PMLiVE

Pfizer and BioNTech’s COVID-19 vaccine begins EMA evaluation

Vaccine is the second to undergo EMA's 'rolling review' process after AstraZeneca/Oxford Uni's candidate

- PMLiVE

Researchers call on Pfizer to delay COVID-19 vaccine application

Reports that the company could seek regulatory approval in October have raised safety concerns

- PMLiVE

BioNTech bolsters COVID-19 vaccine capacity with Novartis deal

Deal will expand production capacity for BNT162b2 candidate

- PMLiVE

Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

Companies share additional phase 1 safety and tolerability data

- PMLiVE

Pfizer, BioNTech identify and advance lead COVID-19 vaccine candidate

Companies pick the most promising candidate to take into phase 2/3

- PMLiVE

US government pays $1.95bn for Pfizer/BioNTech’s COVID-19 vaccine

Initial order includes 100 million doses

- PMLiVE

UK agrees further COVID-19 vaccine deals with Pfizer/BioNTech, Valneva

Government has already agreed similar deal with AstraZeneca

- PMLiVE

GSK agrees on 10% equity stake in mRNA specialist CureVac

Equity investment totals £130m with an upfront payment of £104m

- PMLiVE

FDA fast-tracks Pfizer/BioNTech’s COVID-19 vaccine candidates

Two investigational candidates granted accelerated review

- PMLiVE

Pfizer jumps on early data from BioNTech-partnered COVID-19 vaccine study

Preliminary data demonstrates promising immunogenicity

- PMLiVE

New hires at bluebird bio, BioNTech and Provention Bio

The latest movers in pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links